25 P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth,T. Boon, Science 1991; 254: 1643. 26 V. Brichard, A. Van Pel,T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie,T. Boon, J Exp Med 1993; 178: 489. 27 A. L. Cox, J. Skipper,Y. Chen, R. A. Henderson,T. L. Darrow, J. Shabanowitz,V. H. Engelhard, D. F. Hunt, C. L. Slingluff, Jr, Science 1994; 264: 716. 28 U. Sahin, O. Tureci, H. Schmitt, B. Cochlovius,T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, M. Pfreundschuh, Proc Natl Acad Sci USA 1995; 92: 11810. 29 V. Jongeneel, <strong>Cancer</strong> Immun 2001; 1:3. 30 B. Lethe, S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen,T. Boon, Int J <strong>Cancer</strong> 1998; 76: 903. 31 R. F. Wang, J Mol Med 1999; 77: 640. 32 N. Renkvist, C. Castelli, P. F. Robbins, G. Parmiani, <strong>Cancer</strong> Immunol Immunother 2001; 50:3. 33 A. Townsend, H. Bodmer, Annu Rev Immunol 1989; 7: 601. 34 P. Sliz, O. Michielin, J. C. Cerottini, I. Luescher, P. Romero, M. Karplus, D. C. Wiley, J Immunol 2001; 167: 3276. 35 J. J. Kuhns, M. A. Batalia, S. Yan, E. J. Collins, J Biol Chem 1999; 274: 36422. 36 E. Celis,V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, H. M. Serra, Proc Natl Acad Sci USA 1994; 91: 2105. 37 F. Kern, I. P. Surel, C. Brock, B. Freistedt, H. Radtke, A. Scheffold, R. Blasczyk, P. Reinke, J. Schneider-Mergener, A. Radbruch, P. <strong>Walden</strong>, H. D. Volk, Nat Med 1998; 4: 975. 38 D. Valmori, U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, F. Levy, J Exp Med 1999; 189: 895. 39 M. Ayyoub, M. Migliaccio, P. Guillaume, D. Lienard, J. C. Cerottini, P. Romero, F. Levy, D. E. Speiser, D. Valmori, Eur J Immunol 2001; 31: 2642. References 40 S. Morel, F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A. L. Peitrequin, B. Monsarrat, R. Van Velthoven, J. C. Cerottini, T. Boon, J. E. Gairin, B. J. Van den Eynde, Immunity 2000; 12: 107. 41 J. H. Kessler, N. J. Beekman, S. A. Bres- Vloemans, P. Verdijk, P. A. vanVeelen, A. M. Kloosterman-Joosten, D. C. Vissers, G. J. ten Bosch, M. G. Kester, A. Sijts, J. Wouter Drijfhout, F. Ossendorp, R. Offringa, C. J. Melief, J Exp Med 2001; 193:73. 42 I. Miconnet, C. Servis, J. C. Cerottini, P. Romero, F. Levy, J Biol Chem 2000; 275: 26892. 43 L. Stoltze, A. K. Nussbaum, A. Sijts, N.P.Emmerich,P.M.Kloetzel, H. Schild, Immunol Today 2000; 21:317. 44 J. L. Schultze, R. H. Vonderheide, Trends Immunol 2001; 22: 516. 45 T. Linnemann, S. Tumenjargal, S. Gellrich, K. Wiesmuller, K. Kaltoft,W. Sterry, P. <strong>Walden</strong>, Eur J Immunol 2001; 31: 156. 46 C. Pinilla,V. Rubio-Godoy,V. Dutoit, P. Guillaume, R. Simon,Y. Zhao, R. A. Houghten, J. C. Cerottini, P. Romero, D. Valmori, <strong>Cancer</strong> Res 2001; 61: 5153. 47 Y. Zhao, B. Gran, C. Pinilla, S. Markovic-Plese, B. Hemmer, A. Tzou, L. W. Whitney,W. E. Biddison, R. Martin, R. Simon, J Immunol 2001; 167: 2130. 48 J. D. Altman, P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis, Science 1996; 274: 94. 49 A. J. McMichael, C. A. O'Callaghan, J Exp Med 1998; 187: 1367. 50 M. J. Pittet, D. E. Speiser, D. Valmori, D. Rimoldi, D. Lienard, F. Lejeune, J. C. Cerottini, P. Romero, Int Immunopharmacol 2001; 1: 1235. 51 C. Traversari, P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar- Costesec,T. Boon, J Exp Med 1992; 176: 1453. 52 B. Gaugler, B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur,T. Boon, J Exp Med 1994; 179: 921. 53
54 4 T Cells In Tumor Immunity 53 T. Wolfel, A. Van Pel,V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Buschenfelde,T. Boon, Eur J Immunol 1994; 24: 759. 54 Y. Kawakami, S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, S. A. Rosenberg, J Exp Med 1994; 180: 347. 55 P. G. Coulie,V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C.Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al., J Exp Med 1994; 180: 35. 56 L. Rivoltini,Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, et al., J Immunol 1995; 154: 2257. 57 M. L. Salgaller, A. Afshar, F. M. Marincola, L. Rivoltini,Y. Kawakami, S. A. Rosenberg, <strong>Cancer</strong> Res 1995; 55: 4972. 58 P. Romero, J. C. Cerottini, G. A. Wa<strong>and</strong>ers, Mol Med Today 1998; 4: 305. 59 P. Chaux,V. Vantomme, P. Coulie, T. Boon, P. van der Bruggen, Int J <strong>Cancer</strong> 1998; 77: 538. 60 M. J. Pittet, D. Valmori, P. R. Dunbar, D. E. Speiser, D. Lienard, F. Lejeune, K. Fleischhauer,V. Cerundolo, J. C. Cerottini, P. Romero, J Exp Med 1999; 190: 705. 61 P. R. Dunbar, C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, R. Russell-Jones, A. L. Harris,V. Cerundolo, J Immunol 2000; 165: 6644. 62 P. P. Lee, C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, M. Roederer, M. M. Davis, Nat Med 1999; 5: 677. 63 J. F. Baurain, D. Colau, N. van Baren, C. L<strong>and</strong>ry,V. Martelange, M. Vikkula, T. Boon, P. G. Coulie, J Immunol 2000; 164: 6057. 64 J. J. Molldrem, P. P. Lee, C. Wang, K. Felio, H. M. Kantarjian, R. E. Champlin, M. M. Davis, Nat Med 2000; 6: 1018. 65 V. Karanikas, D. Colau, J. F. Baurain, R. Chiari, J. Thonnard, I. Gutierrez- Roelens, C. Goffinet, E. V. Van Schaftingen, P. Weynants,T. Boon, P. G. Coulie, <strong>Cancer</strong> Res 2001; 61: 3718. 66 D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar,V. Cerundolo, F. Lejeune, J. C. Cerottini, P. Romero, <strong>Cancer</strong> Res 1999; 59: 2167. 67 D. Valmori,V. Dutoit, D. Lienard, D. Rimoldi, M. J. Pittet, P. Champagne, K. Ellefsen, U. Sahin, D. Speiser, F. Lejeune, J. C. Cerottini, P. Romero, <strong>Cancer</strong> Res 2000; 60: 4499. 68 D. Valmori,V. Dutoit,V. Rubio-Godoy, C. Chambaz, D. Lienard, P. Guillaume, P. Romero, J. C. Cerottini, D. Rimoldi, <strong>Cancer</strong> Res 2001; 61: 509. 69 P. G. Coulie,V. Karanikas, D. Colau, C. Lurquin, C. L<strong>and</strong>ry, M. March<strong>and</strong>, T. Dorval,V. Brichard,T. Boon, Proc Natl Acad Sci USA 2001; 98: 10290. 70 Y. Kawakami, N. Dang, X. Wang, J. Tupesis, P. F. Robbins, R. F. Wang, J. R. Wunderlich, J. R. Yannelli, S. A. Rosenberg, J Immunother 2000; 23:17. 71 P.Romero,P.R.Dunbar,D.Valmori, M.Pittet,G.S.Ogg,D.Rimoldi,J.L. Chen,D.Lienard,J.C.Cerottini,V. Cerundolo, J Exp Med 1998; 188: 1641. 72 H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez, M. C. P<strong>and</strong>olfino, M. Bonneville, F. Jotereau, Eur J Immunol 2001; 31: 2007. 73 D. Mumberg, P. A. Monach, S.W<strong>and</strong>erling, M. Philip, A. Y. Toledano, R. D. Schreiber, H. Schreiber, Proc Natl Acad Sci USA 1999; 96: 8633. 74 P. S. Goedegebuure,T. J. Eberlein, Immunol Res 1995; 14: 119. 75 C. Maccalli, R. Mortarini, G. Parmiani, A. Anichini, Int J <strong>Cancer</strong> 1994; 57: 56. 76 S. L. Topalian, L. Rivoltini, M. Mancini, N. R. Markus, P. F. Robbins, Y. Kawakami, S. A. Rosenberg, Proc Natl Acad Sci USA 1994; 91: 9461. 77 S. L. Topalian, M. I. Gonzales, M. Parkhurst,Y. F. Li, S. Southwood, A. Sette, S. A. Rosenberg, P. F. Robbins, J Exp Med 1996; 183: 1965. 78 K. Li, M. Adibzadeh,T. Halder, H. Kalbacher, S. Heinzel, C. Muller, J. Zeuthen, G. Pawelec, <strong>Cancer</strong> Immunol Immunother 1998; 47: 32.
- Page 1 and 2:
Cancer Immune Therapie: Current and
- Page 3 and 4:
Editors: Dr. Gernot Stuhler Univers
- Page 5 and 6:
VI Preface Recent years have seen a
- Page 7 and 8:
VIII Contents 2.5.3 Antigens Encode
- Page 9 and 10:
X Contents 6.4.2 Natural Killer (NK
- Page 11 and 12:
XII Contents 9.6 Loading DC with An
- Page 13 and 14:
XIV Contents 14.2.2.1 Cancer-specif
- Page 15 and 16:
List of Contributors Richard Bucala
- Page 17 and 18:
Color Plates Fig. 5.2 The MHC class
- Page 19 and 20:
Fig. 5.5 Different immune effector
- Page 21 and 22:
Fig. 5.17 Possible pathway for the
- Page 23 and 24:
Fig. 6.2 T lymphocytes in the tumor
- Page 25 and 26:
Index a acidic and basic fibroblast
- Page 27 and 28:
±, see also tumors cationic lipids
- Page 29 and 30:
e EBV see Epstein-Barr virus EDR se
- Page 31 and 32:
immature Mo-DCs 184 immune cells ±
- Page 33 and 34:
MHC class I antigen-processing mach
- Page 35 and 36:
±, onco- 209 ±, over-expressed ce
- Page 37 and 38:
TICD see tumor-induced cell death T
- Page 39 and 40: Part 1 Tumor Antigenicity Cancer Im
- Page 41 and 42: 4 1 Search for Universal Tumor-Asso
- Page 43 and 44: 6 1 Search for Universal Tumor-Asso
- Page 45 and 46: 8 1 Search for Universal Tumor-Asso
- Page 47 and 48: 10 1 Search for Universal Tumor-Ass
- Page 49 and 50: 12 1 Search for Universal Tumor-Ass
- Page 51 and 52: 14 1 Search for Universal Tumor-Ass
- Page 53 and 54: 16 1 Search for Universal Tumor-Ass
- Page 55 and 56: 18 2 Serological Determinants On Tu
- Page 57 and 58: 20 2 Serological Determinants On Tu
- Page 59 and 60: 22 2 Serological Determinants On Tu
- Page 61 and 62: 24 2 Serological Determinants On Tu
- Page 63 and 64: 26 2 Serological Determinants On Tu
- Page 65 and 66: 28 2 Serological Determinants On Tu
- Page 67 and 68: 30 Cancer Immune Therapie: Current
- Page 69 and 70: 32 3 Processing and Presentation of
- Page 71 and 72: 34 3 Processing and Presentation of
- Page 73 and 74: 36 3 Processing and Presentation of
- Page 75 and 76: 38 3 Processing and Presentation of
- Page 77 and 78: 40 Cancer Immune Therapie: Current
- Page 79 and 80: 42 4 T Cells In Tumor Immunity cult
- Page 81 and 82: 44 4 T Cells In Tumor Immunity cell
- Page 83 and 84: 46 4 T Cells In Tumor Immunity to T
- Page 85 and 86: 48 4 T Cells In Tumor Immunity Alth
- Page 87 and 88: 50 4 T Cells In Tumor Immunity Tab.
- Page 89: 52 4 T Cells In Tumor Immunity rest
- Page 93 and 94: Part 2 Immune Evasion and Suppressi
- Page 95 and 96: 60 5 Major Histocompatibility Compl
- Page 97 and 98: 62 5 Major Histocompatibility Compl
- Page 99 and 100: 64 5 Major Histocompatibility Compl
- Page 101 and 102: 66 5 Major Histocompatibility Compl
- Page 103 and 104: 68 Tab. 5.1 HLA class I loss attrib
- Page 105 and 106: 70 5 Major Histocompatibility Compl
- Page 107 and 108: 72 5 Major Histocompatibility Compl
- Page 109 and 110: 74 5 Major Histocompatibility Compl
- Page 111 and 112: 76 5 Major Histocompatibility Compl
- Page 113 and 114: 78 5 Major Histocompatibility Compl
- Page 115 and 116: 80 5 Major Histocompatibility Compl
- Page 117 and 118: 82 5 Major Histocompatibility Compl
- Page 119 and 120: 84 5 Major Histocompatibility Compl
- Page 121 and 122: 86 5 Major Histocompatibility Compl
- Page 123 and 124: 88 5 Major Histocompatibility Compl
- Page 125 and 126: 90 5 Major Histocompatibility Compl
- Page 127 and 128: 92 5 Major Histocompatibility Compl
- Page 129 and 130: 94 5 Major Histocompatibility Compl
- Page 131 and 132: 96 6 Immune Cells in the Tumor Micr
- Page 133 and 134: 98 6 Immune Cells in the Tumor Micr
- Page 135 and 136: 100 6 Immune Cells in the Tumor Mic
- Page 137 and 138: 102 6 Immune Cells in the Tumor Mic
- Page 139 and 140: 104 6 Immune Cells in the Tumor Mic
- Page 141 and 142:
106 6 Immune Cells in the Tumor Mic
- Page 143 and 144:
108 6 Immune Cells in the Tumor Mic
- Page 145 and 146:
110 6 Immune Cells in the Tumor Mic
- Page 147 and 148:
112 6 Immune Cells in the Tumor Mic
- Page 149 and 150:
114 6 Immune Cells in the Tumor Mic
- Page 151 and 152:
116 6 Immune Cells in the Tumor Mic
- Page 153 and 154:
118 6 Immune Cells in the Tumor Mic
- Page 155 and 156:
Tab. 7.1 Effects of tumor-derived m
- Page 157 and 158:
122 7 Immunosuppresive Factors in C
- Page 159 and 160:
124 7 Immunosuppresive Factors in C
- Page 161 and 162:
126 7 Immunosuppresive Factors in C
- Page 163 and 164:
128 7 Immunosuppresive Factors in C
- Page 165 and 166:
130 7 Immunosuppresive Factors in C
- Page 167 and 168:
132 7 Immunosuppresive Factors in C
- Page 169 and 170:
134 7 Immunosuppresive Factors in C
- Page 171 and 172:
136 7 Immunosuppresive Factors in C
- Page 173 and 174:
138 7 Immunosuppresive Factors in C
- Page 175 and 176:
140 7 Immunosuppresive Factors in C
- Page 177 and 178:
142 7 Immunosuppresive Factors in C
- Page 179 and 180:
144 7 Immunosuppresive Factors in C
- Page 181 and 182:
146 7 Immunosuppresive Factors in C
- Page 183 and 184:
148 7 Immunosuppresive Factors in C
- Page 185 and 186:
150 7 Immunosuppresive Factors in C
- Page 187 and 188:
152 7 Immunosuppresive Factors in C
- Page 189 and 190:
154 7 Immunosuppresive Factors in C
- Page 191 and 192:
156 8 Interleukin-10 in Cancer Immu
- Page 193 and 194:
158 8 Interleukin-10 in Cancer Immu
- Page 195 and 196:
160 8 Interleukin-10 in Cancer Immu
- Page 197 and 198:
162 8 Interleukin-10 in Cancer Immu
- Page 199 and 200:
164 8 Interleukin-10 in Cancer Immu
- Page 201 and 202:
166 8 Interleukin-10 in Cancer Immu
- Page 203 and 204:
168 8 Interleukin-10 in Cancer Immu
- Page 205 and 206:
170 8 Interleukin-10 in Cancer Immu
- Page 207 and 208:
172 8 Interleukin-10 in Cancer Immu
- Page 209 and 210:
174 8 Interleukin-10 in Cancer Immu
- Page 211 and 212:
Part 3 Strategies for Cancer Immuno
- Page 213 and 214:
180 9 Dendritic Cells and Cancer: P
- Page 215 and 216:
182 9 Dendritic Cells and Cancer: P
- Page 217 and 218:
184 9 Dendritic Cells and Cancer: P
- Page 219 and 220:
186 9 Dendritic Cells and Cancer: P
- Page 221 and 222:
188 9 Dendritic Cells and Cancer: P
- Page 223 and 224:
190 9 Dendritic Cells and Cancer: P
- Page 225 and 226:
192 9 Dendritic Cells and Cancer: P
- Page 227 and 228:
194 9 Dendritic Cells and Cancer: P
- Page 229 and 230:
196 9 Dendritic Cells and Cancer: P
- Page 231 and 232:
198 9 Dendritic Cells and Cancer: P
- Page 233 and 234:
200 9 Dendritic Cells and Cancer: P
- Page 235 and 236:
202 9 Dendritic Cells and Cancer: P
- Page 237 and 238:
204 Cancer Immune Therapie: Current
- Page 239 and 240:
206 10 The Immune System in Cancer:
- Page 241 and 242:
208 10 The Immune System in Cancer:
- Page 243 and 244:
210 10 The Immune System in Cancer:
- Page 245 and 246:
212 10 The Immune System in Cancer:
- Page 247 and 248:
214 10 The Immune System in Cancer:
- Page 249 and 250:
216 10 The Immune System in Cancer:
- Page 251 and 252:
218 10 The Immune System in Cancer:
- Page 253 and 254:
220 10 The Immune System in Cancer:
- Page 255 and 256:
222 10 The Immune System in Cancer:
- Page 257 and 258:
224 10 The Immune System in Cancer:
- Page 259 and 260:
226 10 The Immune System in Cancer:
- Page 261 and 262:
228 10 The Immune System in Cancer:
- Page 263 and 264:
230 Cancer Immune Therapie: Current
- Page 265 and 266:
232 11 Hybrid Cell Vaccination for
- Page 267 and 268:
234 11 Hybrid Cell Vaccination for
- Page 269 and 270:
236 11 Hybrid Cell Vaccination for
- Page 271 and 272:
238 11 Hybrid Cell Vaccination for
- Page 273 and 274:
240 11 Hybrid Cell Vaccination for
- Page 275 and 276:
242 11 Hybrid Cell Vaccination for
- Page 277 and 278:
244 11 Hybrid Cell Vaccination for
- Page 279 and 280:
246 11 Hybrid Cell Vaccination for
- Page 281 and 282:
248 11 Hybrid Cell Vaccination for
- Page 283 and 284:
250 11 Hybrid Cell Vaccination for
- Page 285 and 286:
252 11 Hybrid Cell Vaccination for
- Page 287 and 288:
254 12 Principles and Strategies Em
- Page 289 and 290:
256 12 Principles and Strategies Em
- Page 291 and 292:
258 12 Principles and Strategies Em
- Page 293 and 294:
260 12 Principles and Strategies Em
- Page 295 and 296:
262 12 Principles and Strategies Em
- Page 297 and 298:
264 12 Principles and Strategies Em
- Page 299 and 300:
266 12 Principles and Strategies Em
- Page 301 and 302:
268 Cancer Immune Therapie: Current
- Page 303 and 304:
270 13 Applications of CpG Motifs f
- Page 305 and 306:
272 13 Applications of CpG Motifs f
- Page 307 and 308:
274 13 Applications of CpG Motifs f
- Page 309 and 310:
276 13 Applications of CpG Motifs f
- Page 311 and 312:
278 13 Applications of CpG Motifs f
- Page 313 and 314:
280 13 Applications of CpG Motifs f
- Page 315 and 316:
282 13 Applications of CpG Motifs f
- Page 317 and 318:
284 13 Applications of CpG Motifs f
- Page 319 and 320:
286 13 Applications of CpG Motifs f
- Page 321 and 322:
288 14 The T-Body Approach: Towards
- Page 323 and 324:
290 14 The T-Body Approach: Towards
- Page 325 and 326:
292 14 The T-Body Approach: Towards
- Page 327 and 328:
294 14 The T-Body Approach: Towards
- Page 329 and 330:
296 14 The T-Body Approach: Towards
- Page 331 and 332:
298 14 The T-Body Approach: Towards
- Page 333 and 334:
300 15 Bone Marrow Transplantation
- Page 335 and 336:
302 15 Bone Marrow Transplantation
- Page 337 and 338:
304 15 Bone Marrow Transplantation
- Page 339 and 340:
306 15 Bone Marrow Transplantation
- Page 341 and 342:
308 15 Bone Marrow Transplantation
- Page 343 and 344:
310 15 Bone Marrow Transplantation
- Page 345 and 346:
312 16 Immunocytokines: Versatile M
- Page 347 and 348:
314 16 Immunocytokines: Versatile M
- Page 349 and 350:
316 16 Immunocytokines: Versatile M
- Page 351 and 352:
318 16 Immunocytokines: Versatile M
- Page 353 and 354:
320 16 Immunocytokines: Versatile M
- Page 355 and 356:
322 16 Immunocytokines: Versatile M
- Page 357 and 358:
324 16 Immunocytokines: Versatile M
- Page 359 and 360:
326 16 Immunocytokines: Versatile M
- Page 361 and 362:
328 16 Immunocytokines: Versatile M
- Page 363 and 364:
330 16 Immunocytokines: Versatile M
- Page 365 and 366:
332 16 Immunocytokines: Versatile M
- Page 367 and 368:
334 16 Immunocytokines: Versatile M
- Page 369 and 370:
336 16 Immunocytokines: Versatile M
- Page 371 and 372:
338 16 Immunocytokines: Versatile M
- Page 373 and 374:
340 16 Immunocytokines: Versatile M
- Page 375 and 376:
342 16 Immunocytokines: Versatile M
- Page 377 and 378:
344 16 Immunocytokines: Versatile M
- Page 379 and 380:
346 16 Immunocytokines: Versatile M
- Page 381 and 382:
348 17 Immunotoxins and Recombinant
- Page 383 and 384:
350 17 Immunotoxins and Recombinant
- Page 385 and 386:
352 17 Immunotoxins and Recombinant
- Page 387 and 388:
354 17 Immunotoxins and Recombinant
- Page 389 and 390:
356 17 Immunotoxins and Recombinant
- Page 391 and 392:
358 17 Immunotoxins and Recombinant
- Page 393 and 394:
360 17 Immunotoxins and Recombinant
- Page 395 and 396:
362 17 Immunotoxins and Recombinant
- Page 397 and 398:
364 17 Immunotoxins and Recombinant
- Page 399 and 400:
366 17 Immunotoxins and Recombinant
- Page 401 and 402:
368 17 Immunotoxins and Recombinant
- Page 403 and 404:
370 17 Immunotoxins and Recombinant
- Page 405 and 406:
372 17 Immunotoxins and Recombinant
- Page 407 and 408:
374 17 Immunotoxins and Recombinant
- Page 409 and 410:
376 17 Immunotoxins and Recombinant
- Page 411 and 412:
378 17 Immunotoxins and Recombinant
- Page 413 and 414:
380 Cancer Immune Therapie: Current
- Page 415 and 416:
382 Glossary tion to the variable d
- Page 417 and 418:
384 Glossary suppressor gene produc
- Page 419 and 420:
386 Glossary press the proper recep
- Page 421 and 422:
388 Glossary gp96 See Chaperone. Gr
- Page 423 and 424:
390 Glossary cytes and addressing l
- Page 425 and 426:
392 Glossary T bodies are being tes